IDEXX Laboratories, Inc. (IDXX) Guidance & Earnings Results

On 2026-08-04 IDEXX Laboratories, Inc. raised guidance: "Revenue guidance raised $5M at midpoint to $4,700M-$4,745M; EPS raised $0.14 to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

IDXXIDEXX Laboratories, Inc.Follow IDXX — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 44.1B
P/E TTM: 39.4
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	Revenue guidance raised $5M at midpoint to $4,700M-$4,745M; EPS raised $0.14 to $14.69-$14.94 · full year
5 May 26	Raised	Revenue guidance raised by ~$42M at midpoint; EPS guidance raised by $0.13 at midpoint · full year
2 Feb 26	Raised	2026 revenue guidance $4,632M-$4,720M (7.6%-9.6% growth); EPS $14.29-$14.80 (+9%-13%)
3 Nov 25	Raised	FY2025 revenue guidance raised by $43M to $4.27B-$4.30B, EPS raised by $0.33 to $12.81-$13.01 · full year
4 Aug 25	Raised	FY2025 revenue raised to $4,205-4,280M from $4,115-4,190M (implied prior midpoint $4,152.5M); FY2025 EPS raised to $12.40-12.76 from $12.00-12.36 (implied prior midpoint $12.18); FY2025 organic revenue growth raised to 7.0-9.0% from 6.5-8.5%; FY2025 CAG Diagnostics recurring revenue organic growth refined to 5.8-8.0% from prior range. · full year

IDEXX Laboratories, Inc. — questions

What guidance did IDEXX Laboratories, Inc. give?: On 2026-08-04: "Revenue guidance raised $5M at midpoint to $4,700M-$4,745M; EPS raised $0.14 to $14.69-$14.94"
When does IDEXX Laboratories, Inc. report earnings?: IDEXX Laboratories, Inc.'s next earnings report is expected on 2026-11-02.

Every figure on this page comes from IDEXX Laboratories, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.